

SEARCH REQUEST FORM

151109

Requestor's
Name: _____

BERCH


Serial
Number:

10606424

Date: 4/19 Phone: 571-272-0663 Art Unit: 1624
Office Res 5C01 Mailbox 5C18

Search Topic:

Search Topic: Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s). CH₂



Compound cannot

be multicomponent

330.70

11:49
7:47




3 of 4

Page 1

=> d 110 que stat;fil caplus;s 110
L5 STR

Buch
10/606424

#304



VAR G1=19/30/40

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L7 595 SEA FILE=REGISTRY SSS FUL L5

L8 451 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND 1/NC
L9 STR



VAR G1=19/30/40

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L10 22 SEA FILE=REGISTRY SUB=L8 SSS FUL L9

100.0% PROCESSED 22 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

330.70

330.91

FILE 'CAPLUS' ENTERED AT 11:48:51 ON 21 APR 2005

USE_IS SUBJECT_TO_THE_TERMS_OF_YOUR_STN_CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Page 3

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2005 VOL 142 ISS 17
FILE LAST UPDATED: 20 Apr 2005 (20050420/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


L11 5 L10

=> d 1-5 ibib abs hitstr

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005161015 CAPLUS
 DOCUMENT NUMBER: 142:261551
 TITLE: Preparation of purinamines as inhibitors of receptor tyrosine kinase activity
 INVENTOR(S): Cheng, Dai; Ding, Qiang; Han, Dong; Gray, Nathanael
 Schiander, Zhang, Guobao
 IRM Llc, Bermuda
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016528	A2	20050224	WO 2004-US26373	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OH, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-495406P	P 20030815
			US 2003-524357P	P 20031121
			US 2004-565367P	P 20040426

GI




AB The invention provides a novel class of compds. I [R1 = H, halo, alkyl, haloalkyl, etc.; R2 = H, aryl, heteroaryl; R3 = H, alkyl; R4 = (hetero)cycloalkylalkyl, (hetero)aryalkyl, etc.], pharmaceutical compds. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with cSRC, Lck, FGFR3, Flt3, TrkB, Bmx, and/or PDGFR α kinase activity. Twelve synthetic examples

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 describe the prep. of compds. I. E.g., a multi-step synthesis of II, starting from 2,6-dichloropurine, was given. The compds. I were tested against various kinases. For example, I showed IC₅₀ of 0.1 nM to 0.0005 μ M in Flt-3 assay.
 IT 845792-02-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of purinamines as tyrosine kinase receptor inhibitors)
 RN 845792-02-1 CAPLUS
 CN Piperidine, 1-[(2-[(4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]benzyl (SCI) (CA INDEX NAME)




IT 845795-66-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of purinamines as tyrosine kinase receptor inhibitors)
 RN 845795-66-6 CAPLUS
 CN Piperidine, 1-[(4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]benzyl) (SCI) (CA INDEX NAME)

Relative stereochemistry.

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:221651 CAPLUS
 DOCUMENT NUMBER: 138:238196

TITLE: Preparation of biaryl methylaminopurines as potent cyclin/CDK inhibitors and antiproliferative agents.
 INVENTOR(S): Trova, Michael Peter
 PATENT ASSIGNEE(S): Albany Molecular Research, Inc., USA
 SOURCE: PCT Int. Appl., 275 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022805	A2	20030320	WO 2002-US28730	20020909
WO 2003022805	A3	20040412		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003092909	A1	20030515	US 2002-237530	20020906
US 6812232	B2	20041102		
PRIORITY APPLN. INFO.:			US 2001-318569P	P 20010911
OTHER SOURCE(S):			MARPAT 138:238196	
GI				



AB Title compds. [I; R1 = H, alkyl, alkaryl, cycloalkyl, CH₂CF₃, CH₂CH₂CF₃, CH(CF₃)₂; R2 = (substituted) Ph, naphthyl, pyridyl, pyrimidyl, thieryl, furyl, pyrrolyl, quinolinyl, isoquinolinyl, etc.; R3 = H, alkyl, alketyl, (substituted) Ph, phenylalkyl, etc.; R4 = H, alkyl; R3R4 = atoms to form a 5-8 membered ring; R5 = heterocycle; A = CH₂, (CH₂)₂, (CH₂)₃, OCH₂CH₂, CH₂CH₃; Y = H, OR₁, NHCOR₃, NH₂SO₂R₃, etc.; Q = (CH₂)_n n = 0-3; V = NH, O, S, CH₂], were prepared. Thus, title compound II was prepared and inhibited growth of BT-579, MCF7, and numerous other transformed cell lines with GI₅₀ < 0.01 μ M.

IT 502146-09-0

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biarylmethylenopurines as potent cyclin/CDK inhibitors

and antiproliferative agents)

RN 502146-09-0 CAPLUS

CN 7H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(4-(5-chloro-2-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

TITLE: Preparation of biarylmethylenopurines as potent cyclin/CDK inhibitors and antiproliferative agents

INVENTOR(S): Trova, Michael Peter

PATENT ASSIGNEE(S): Albany Molecular Research, Inc., USA

SOURCE: PCT Int. Appl., 266 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022219	A2	20030320	WO 2002-U528731	20020909
WO 2003022219	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NU, NZ, OM, PR, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, S2, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, MR, NE, SN, TD, TG				
US 2003087906	A1	20030508	US 2001-950543	20010911
US 6667311	B2	20031223		
US 2004077666	A1	20040422	US 2003-680832	20031007
PRIORITY APPLN. INFO.:			US 2001-950543	A 20010911
OTHER SOURCE(S):			MARPAT 138:255243	

GI



AB The compds. I of the present invention are 2,6,9-trisubstituted purine derivs. which are inhibitors of cyclin/CDK complexes. Title compds. I (R1 = H, alkyl, alkaryl, cycloalkyl, CH₂CF₃, CH₂CH₂CF₃, CH(CF₃)₂; R2 = (substituted) Ph, naphthyl, pyridyl, pyrimidyl, thieryl, furyl, pyrrolyl, quinolinyl, isoquinolinyl, etc.; R3 = H, alkyl, alketyl, (substituted) Ph, phenylalkyl, etc.; R4 = H, alkyl; R3R4 = form a 5-8 membered ring; R5 = heterocycle; A = CH₂, (CH₂)₂, (CH₂)₃, OCH₂CH₂, CH₂CH₃; Y = H, OR₁, NHCOR₃, NH₂SO₂R₃, etc.; Q = (CH₂)_n n = 0-3; V = NH, O, S, CH₂], were prepared. Thus, title compound II was prepared and inhibited growth of

BT-579, MCF7, and numerous other transformed cell lines with GI₅₀ < 0.01 μ M.

The compds. of the current invention also are potent inhibitors of human cellular proliferation. As such, the compds. of the present invention constitute pharmaceutical compns. with a pharmaceutically acceptable carrier. Such compds. are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound

IT 502146-09-0

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of biarylmethylenopurines as potent cyclin/CDK inhibitors

and antiproliferative agents)

RN 502146-09-0 CAPLUS

CN 7H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(4-(5-chloro-2-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:504788 CAPLUS
 DOCUMENT NUMBER: 137:78809
 TITLE: Method of preparation of novel purine derivatives and their use as antifungal medicines
 INVENTOR(S): Bordon-Fallier, Florence; Haeslein, Jean-Luc
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXMD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051843	A1	20020704	WO 2001-FR4051	20011219
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
FR 2818642	A1	20020628	FR 2000-17009	20001226
CA 2433220	AA	20020704	CA 2001-2433220	20011219
EP 1347975	A1	20031001	EP 2001-994897	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004516326	T2	20040603	JP 2002-552938	20011219
US 2004063732	A1	20040401	US 2003-606424	20030626
PRIORITY APPLN. INFO.:			FR 2000-17009	A 20001226
			WO 2001-FR4051	W 20011219

OTHER SOURCE(S): CASREACT 137:78809, MARPAT 137:78809
 GI



I

AB The invention concerns novel purine products I [Rx = (2)NRL; Z = CH2, SO2, CO, CO2, CONH, (CH2)2-NR6; n = 0, 1; R1 = H, Ph, CH2Ph, pyridyl, alkyl, piperidinyl (optionally substituted); Ry = (un)substituted Ph, Rz; D1, D2 = H, (un)substituted NH2], in all the isomeric forms and pharmaceutically acceptable salts, for use as antifungal medicines. Thus, trans-N2-(4-aminocyclohexyl)-N6-(3,4-dichlorophenyl)-9H-purin-6-amine (I, Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was prepared from


L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 2,6-dichloropurine via amination with 3,4-dichloroaniline in BuOH followed by fusion with trans-1,4-diaminocyclohexane at 70°. I (Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was shown to be an active inhibitor of CIV-CDK (CIV) [$IC50 = 2.9 \mu M$] and Candida albicans [CMI = 25 μM /ml].

IT 439803-06-2P 439803-12-0P 439803-14-2P
 439803-17-5P 439803-19-7P 439803-21-1P
 439803-23-3P 439803-25-5P 439803-27-8P
 439803-29-9P 439803-31-3P 439803-33-5P
 439803-42-6P

RL: BSG (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of novel purine derivs. as inhibitors of CIV-CDK)

RN 439803-06-2 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-12-0 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 439803-19-7 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439803-21-1 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-17-5 CAPLUS
 CN Benzoic acid, 3-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439803-25-5 CAPLUS
 CN Benzoic acid, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-27-7 CAPLUS
 CN Benzamide, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-N-phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzanilide, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439803-42-6 CAPLUS
 CN Benzoic acid, 4-[(2-(cyclohexylamino)-1H-purin-6-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT:

5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 439803-29-9 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439803-31-3 CAPLUS
 CN Benzaldehyde, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439803-33-5 CAPLUS

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1973:16123 CAPLUS
 DOCUMENT NUMBER: 78:16123

TITLE: Synthesis and study of 2,6-diaminopurines
 AUTHOR(S): Tret'yakova, G. S.; Nedel'kina, N. N.; Cherkasov, V. M.

CORPORATE SOURCE: Inst. Org. Khim., Kiev, USSR
 SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition)
 (1972), 38(6), 602-5

CODEN: UXZHOU; ISSN: 0041-6045

DOCUMENT TYPE: Journal


LANGUAGE: Russian

AB 2,6-Dichloropurine was treated with cyclohexyl-, adamantyl-, and benzylamines, and with morpholine, p-toluidine, and p-nitroaniline to replace the Cl atom in position 2. By use of more amine, disubstituted compds. were obtained using morpholine, benzylamine, and p-toluidine. The Cl atom of 6-chloro-2-benzylaminopurine was replaced by p-XC6H4NH (X = Me, NO2) and the Cl of 6-chloro-2-cyclohexylaminopurine was replaced with p-O2NC6H4NH. These compds. were prepared as substances with possible cytosine activity.

IT 39639-51-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 39639-51-5 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-cyclohexyl-N6-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



Page 8

=> fil caol;s 111
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.15	356.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	-3.65	-3.65

FILE 'CAOLD' ENTERED AT 11:49:39 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L12 0 L10

=> del his y

=> fil reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	356.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'REGISTRY' ENTERED AT 11:49:57 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with _IC are from the ZIG/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2005 HIGHEST RN 848887-73-0
DICTIONARY FILE UPDATES: 20 APR 2005 HIGHEST RN 848887-73-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

SEARCH REQUEST FORM

15112

Requestor's
Name:

BERCH

Serial

Number:

1060642X

Date:

4/19/88



Phone: 571-272-0663 Art Unit: 1624

Office Room 5C01

Mailbox 5C18

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).




4 of 4

Page 1

```
=> d 15 que stat;fil caplus;s 15
L1                      STR
```

Buch
10/606 424

#4 of 4



2 = VAR G1 = 28/19

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L3 50 SEA FILE=REGISTRY SSS FUL L1
L4 STR



Page 2

O---C---O~Ak
31 @32 33 34

Page 2-A
VAR G1=28/19
VPA 32-13/12/11 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
L5 6 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED 50 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	203.68	963.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

FILE 'CAPLUS' ENTERED AT 12:18:21 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2005 VOL 142 ISS 17
FILE LAST UPDATED: 20 Apr 2005 (20050420/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Page 8


L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:504788 CAPLUS
 DOCUMENT NUMBER: 137:78809
 TITLE: Method of preparation of novel purine derivatives and
 their use as antifungal medicines
 INVENTOR(S): Bordon-Pallier, Florence; Haesslein, Jean-Luc
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXKD2

DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051843	A1	20020704	WO 2001-FR4051	20011219
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, SV, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: CH, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CO, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2818642		20020628	FR 2000-17009	20001226
CA 2433220	AA	20020704	CA 2001-2433220	20011219
EP 1347975	A1	20031001	EP 2001-994857	20011219
R: AE, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004516326	T2	20040603	JP 2002-552938	20011219
US 2004063732	A1	20040401	US 2003-606424	20030626
PRIORITY APPLN. INFO.:			FR 2000-17009	A 20001226
			WC 2001-FR4051	W 20011219

OTHER SOURCE(S): CASREACT 137:78809; MARPAT 137:78809


GI




I

AB The invention concerns novel purine products I [Rx = (2)NR1; Z = CH2, SO2, CO, CO2, CONH, (CH2)nNR6; n = 0, 1; R1 = H, Ph, CH2Ph, pyridyl, alkyl, piperidinyl (optionally substituted); Ry = (un)substituted Ph, Rz; D1, D2 = H, (un)substituted NH2], in all the isomeric forms and pharmaceutically acceptable salts, for use as antifungal medicines. Thus,

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439803-39-1 CAPLUS
 CN Benzoic acid, 4-[(2-[(3-aminophenyl)amino]-1H-purin-6-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 439803-40-4 CAPLUS
 CN Benzoic acid, 4-[(2-[(dimethylamino)phenyl]amino)-1H-purin-6-yl]amino-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 trans-N2-(4-aminocyclohexyl)-N6-(3,4-dichlorophenyl)-9H-purin-6-amine (I; Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was prep'd. from 2,6-dichloropurine via amination with 3,4-dichloroaniline in BuOH followed by fusion with trans-1,4-diaminocyclohexane at 70°. I (Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was shown to be an active inhibitor of CIV-CDK (CIV1) [$IC50 = 2.9 \mu M$] and Candida albicans [CMI = 25 $\mu M/mL$].

IT 439803-37-9P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel purine derivs. as inhibitors of CIV-CDK)


RN 439803-37-9 CAPLUS
 CN Benzoic acid, 4-[(2-[(3-nitrophenyl)amino]-1H-purin-6-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 439803-35-7P 439803-39-1P 439803-40-4P
 439803-42-6P 439803-44-8P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel purine derivs. as inhibitors of CIV-CDK)

RN 439803-35-7 CAPLUS
 CN Benzoic acid, 4,4'-(1H-purin-2,6-diylidimino)bis-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 439803-42-6 CAPLUS
 CN Benzoic acid, 4-[(2-(cyclohexylamino)-1H-purin-6-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 439803-44-8 CAPLUS
 CN Benzoic acid, 3-[(6-[(4-(ethoxycarbonyl)phenyl)amino]-1H-purin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

Page 9

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Page 10

=> fil caol;s 17
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.29	970.14
CA SUBSCRIBER PRICE	-0.73	-13.87

FILE 'CAOLD' ENTERED AT 12:20:17 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L8 0 L5

=> fil reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	970.57
CA SUBSCRIBER PRICE	0.00	-13.87

FILE 'REGISTRY' ENTERED AT 12:20:22 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2005 HIGHEST RN 848887-73-0
DICTIONARY FILE UPDATES: 20 APR 2005 HIGHEST RN 848887-73-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Page 11

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****  
*  
* The CA roles and document type information have been removed from *  
* the IDE default display format and the ED field has been added, *  
* effective March 20, 2005. A new display format, IDERL, is now *  
* available and contains the CA role and document type information. *  
*  
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> dis his

FILE 'REGISTRY' ENTERED AT 12:11:32 ON 21 APR 2005
DEL HIS Y


FILE 'REGISTRY' ENTERED AT 12:11:46 ON 21 APR 2005
L1 STR
L2 1 S L1
L3 50 S L1 FUL
L4 STR L1
L5 6 SEARCH L4 SUB=L3 FUL

FILE 'CAPLUS' ENTERED AT 12:18:21 ON 21 APR 2005
L6 1 S L5
L7 1 S L5

FILE 'CAOLD' ENTERED AT 12:20:17 ON 21 APR 2005
L8 0 S L7

FILE 'REGISTRY' ENTERED AT 12:20:22 ON 21 APR 2005

=> d 15 que stat
L1 STR



VAR G1=28/19

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L3 50 SEA FILE=REGISTRY SSS FUL L1
L4 STR



Page 13

O---C---O~Ak
31 @32 33 34

Page 2-A
VAR G1=28/19
VPA 32-13/12/11 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
L5 6 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED 50 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.43	971.00
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.87

STN INTERNATIONAL LOGOFF AT 12:20:32 ON 21 APR 2005

SEARCH REQUEST FORM

15111







Requestor's
Name: BERCH

Serial
Number: 10 606424

Date: 4/19 Phone: 571-272-0663 Art Unit: 1624
Office Rem 5C01 Mailbox 5C18

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).



Compound must be mult. component

Do not broaden search

16a.50
26.01
13.03

12.11
12.08
12.11






#2 of 4

Page 1

Buch
10/606424

2 of 4

=> d 13 que stat;fil caplus;s 13
L1 STR



NH2 @62

VAR G1=NH2/60/48/49/52/61

VAR G2=NH2/52

VAR G3=ET/I-PR/N-PR

VPA 62-14/13/18 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

L3 34 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 302 ITERATIONS

SEARCH TIME: 00.00.01

34 ANSWERS

COST-IN-U.S.-DOLLARS

SINCE-FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

169.50

739.10

DISCOUNT AMOUNTS-(FOR-QUALIFYING-ACCOUNTS)

SINCE-FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY

SESSION

0.00

-10.22

FILE 'CAPLUS' ENTERED AT 12:11:15 ON 21 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Page 2

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2005 VOL 142 ISS 17
FILE LAST UPDATED: 20 Apr 2005 (20050420/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


L4 4 L3

=> d 1-4 ibib abs hitstr;fil caol;s 13

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005161015 CAPLUS
 DOCUMENT NUMBER: 142:261551
 TITLE: Preparation of purinamines as inhibitors of receptor tyrosine kinase activity
 INVENTOR(S): Cheng, Dai; Ding, Qiang; Han, Dong; Gray, Nathanael Schiander, Bernhard
 PATENT ASSIGNEE(S): IRM Lic, Bermuda
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016528	A2	20050224	WO 2004-US26373	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UC, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, IG	US 2003-495406P	P	20030815	
PRIORITY APPLN. INFO.:		US 2003-524357P	P	20031121
		US 2004-565367P	P	20040426

GI




AB The invention provides a novel class of compds. I [R1 = H, halo, alkyl, haloalkyl, etc.; R2 = H, aryl, heteroaryl; R3 = H, alkyl; R4 = (hetero)cycloalkylalkyl, (hetero)arylsalkyl, etc.], pharmaceutical compds. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with cSRC, Lck, FGFR3, Flt3, TrkB, Bmx, and/or PDGFR α kinase activity. Twelve synthetic examples

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 describe the prepn. of compds. I. E.g., a multi-step synthesis of II, starting from 2,6-dichloropurine, was given. The compds. I were tested against various kinases. For example, I showed IC₅₀ of 0.1 nM to 0.0005 μ M in Flt-3 assay.

IT 845792-02-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of purinamines as tyrosine kinase receptor inhibitors)

RN 845792-02-1 CAPLUS
 CN Piperidine, 1-[4-[(2-[(4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)




IT 845795-66-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of purinamines as tyrosine kinase receptor inhibitors)

RN 845795-66-6 CAPLUS
 CN Piperidine, 1-[4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]benzoyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:221651. CAPLUS
 DOCUMENT NUMBER: 138:238196
 TITLE: Preparation of biaryl methylaminopurines as potent cyclin/CDK inhibitors and antiproliferative agents.

INVENTOR(S): Trova, Michael Peter
 PATENT ASSIGNEE(S): Albany Molecular Research, Inc., USA
 SOURCE: PCT Int. Appl., 275 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022805	A2	20030320	WO 2002-US28730	20020909
WO 2003022805	A3	20040122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	US 2003092909	A1 20030515 US 2002-237530	20020906	
US 6812323	B2	20041102		
PRIORITY APPLN. INFO.:			US 2001-318569P	P 20010911
OTHER SOURCE(S):			MARPAT 138:238196	
GI				



AB Title compds. [I]: R1 = H, alkyl, alkenyl, cycloalkyl, CH2CF3, CH2CH2CF3, CH(CF3)2; R2 = (substituted) Ph, naphthyl, pyridyl, pyrimidyl, thienvyl, furyl, pyrrolyl, quinolinyl, isoquinolinyl, etc.; R3 = H, alkyl, alkenyl, (substituted) Ph, phenylalkyl, etc.; R4 = H, alkyl; R3R4 = atoms to form a 5-8 membered ring; R5 = heterocycle; A = CH2, (CH2)2, (CH2)3, OCH2CH2, CHCH3; Y = H, OR1, NHRI, NHCOR3, etc.; Q = (CH2)n; n = 0-3; V = NH, O, S, CH2, were prepared. Thus, title compound II was prepared and inhibited growth of BT-579, MCF7, and numerous other transformed cell lines with GI50 < 0.01 μ M.

IT 502146-09-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biarylmethylenopurines as potent cyclin/CDK inhibitors and antiproliferative agents)

RN 502146-09-0 CAPLUS

CN 7H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(4-(5-chloro-2-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

TITLE: Preparation of biarylmethylenopurines as potent cyclin/CDK inhibitors and antiproliferative agents

INVENTOR(S): Trova, Michael Peter

PATENT ASSIGNEE(S): Albany Molecular Research, Inc., USA

SOURCE: PCT Int. Appl., 266 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022219	A2	20030320	WO 2002-US28731	20020909
WO 2003022219	A3	20031113		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, S2, TZ, UG, ZM, ZW, AM, AZ, BY, XG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2003087906	A1	20030508	US 2001-950543	20010911
US 6667311	B2	20031223		
US 2004077666	A1	20040422	US 2003-680832	20031007
PRIORITY APPLN. INFO.:			US 2001-950543	A 20010911
OTHER SOURCE(S): MARPAT 138:255243				
GI				



AB The compds. I of the present invention are 2,6,9-trisubstituted purine derivs., which are inhibitors of cyclin/CDK complexes. Title compds. I [R1 = H, alkyl, alkenyl, cycloalkyl, CH2CF3, CH2CH2CF3, CH(CF3)2; R2 = (substituted) Ph, naphthyl, pyridyl, pyrimidyl, thienvyl, furyl, pyrrolyl, quinolinyl, isoquinolinyl, etc.; R3 = H, alkyl, alkenyl, (substituted) Ph, phenylalkyl, etc.; R4 = H, alkyl; R3R4 = form a 5-8 membered ring; R5 = heterocycle; A = CH2, (CH2)2, (CH2)3, OCH2CH2, CHCH3; Y = H, OR1, NHRI, NHCOR3, etc.; Q = (CH2)n; n = 0-3; V = NH, O, S, CH2, were prepared. Thus, title compound II was prepared and inhibited growth of

BT-579, and numerous other transformed cell lines with GI50 < 0.01 μ M.

The compds. of the current invention also are potent inhibitors of human cellular proliferation. As such, the compds. of the present invention constitute pharmaceutical compds. with a pharmaceutically acceptable carrier. Such compds. are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound

IT 502146-09-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biarylmethylenopurines as potent cyclin/CDK inhibitors and antiproliferative agents)

RN 502146-09-0 CAPLUS

CN 7H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(4-(5-chloro-2-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:504788 CAPLUS

DOCUMENT NUMBER: 137:78809

TITLE: Method of preparation of novel purine derivatives and their use as antifungal medicines
INVENTOR(S): Bordon-Pallier, Florence; Haesslein, Jean-Luc
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051843	A1	20020704	WO 2001-FR4051	20011219
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DN, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
FR 2818642	A1	20020628	FR 2000-17009	20001226
CA 2433220	AA	20020704	CA 2001-2433220	20011219
EP 1347975	A1	20031001	EP 2001-994897	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004516326	T2	20040603	JP 2002-552938	20011219
US 2004063732	A1	20040401	US 2003-606424	20030626
PRIORITY APPLN. INFO.:			FR 2000-17009	A 20001226
			WO 2001-FR4051	W 20011219

OTHER SOURCE(S): CASREACT 137:78809; MARPAT 137:78809
GI




I

7/15

AB The invention concerns novel purine products I [Rx = (2)NRI; Z = CH2, SO2, CO, CO2, CONH, (CH2)2-NR6; n = 0, 1; RI = H, Ph, CH2Ph, pyridyl, alkyl, piperidinyl (optionally substituted); Ry = (un)substituted Ph, Rz; D1, D2 = H, (un)substituted NH2], in all the isomeric forms and pharmaceutically acceptable salts, for use as antifungal medicines. Thus, trans-N2-(4-aminocyclohexyl)-N6-(3,4-dichlorophenyl)-9H-purin-6-amine (I; Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was prepared from


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●3 HCl

RN 439802-94-5 CAPLUS
CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-propyl-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●2 HCl

RN 439802-96-7 CAPLUS
CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 439802-98-9 CAPLUS
CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-(4-methoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
2,6-dichloropurine via amination with 3,4-dichloraniline in BuOH followed by fusion with trans-1,4-diaminocyclohexane at 70°. I (Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was shown to be an active inhibitor of CIV-CDK (CIV1) [$IC_{50} = 2.9 \mu M$] and Candida albicans [CMI = 25 $\mu g/mL$].


IT 439802-90-1P 439802-92-3P 439802-94-5P
439802-96-7P 439802-98-9P 439803-00-6P
439803-02-8P 439803-04-0P 439803-06-2P
439803-08-4P 439803-10-8P 439803-12-0P
439803-17-5P 439803-19-7P 439803-21-1P
439803-23-3P 439803-25-5P 439803-27-7P
439803-29-9P 439803-31-3P 439803-33-5P

RL (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of novel purine derivs. as inhibitors of CIV-CDK)

RN 439802-90-1 CAPLUS

CN Benzonic acid, 2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl]amino-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 439802-92-3 CAPLUS

CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-(2-aminoethyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



●2 HCl

RN 439803-00-6 CAPLUS
CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[4-(trifluoromethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl


RN 439803-02-8 CAPLUS
CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[1-(phenylmethyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HCl

RN 439802-98-9 CAPLUS
CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-(4-methoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 3 HCl

RN 439803-04-0 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(2-[(phenylmethyl)amino]ethyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 3 HCl

RN 439803-06-2 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(3,4-dimethoxyphenyl)methyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 2 HCl


RN 439803-12-0 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(4-fluorophenyl)methyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-17-5 CAPLUS
 CN Benzoic acid, 3-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-19-7 CAPLUS

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439803-08-4 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 439803-10-8 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.




RN 439803-21-1 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-[(3,4-dichlorophenyl)methyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-23-3 CAPLUS
 CN Benzoic acid, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-, butyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 439803-25-5 CAPLUS
 CN Benzoic acid, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439803-27-7 CAPLUS
 CN Benzamide, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]-N-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 439803-29-9 CAPLUS
 CN 1H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-N6-{4-(dimethylamino)phenyl}- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 439803-31-3 CAPLUS
 CN Benzaldehyde, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439803-33-5 CAPLUS
 CN Benzamide, 4-[(2-[(trans-4-aminocyclohexyl)amino]-1H-purin-6-yl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION

FILE 'CAOLD' ENTERED AT 12:11:26 ON 21 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Page 8

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	759.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

FILE 'REGISTRY' ENTERED AT 12:11:32 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2005 HIGHEST RN 848887-73-0
DICTIONARY FILE UPDATES: 20 APR 2005 HIGHEST RN 848887-73-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> dis his

(FILE 'CAOLD' ENTERED AT 11:57:32 ON 21 APR 2005)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 11:58:58 ON 21 APR 2005

L1 STR
L2 1 S L1
L3 34 S L1 FUL



FILE 'CAPLUS' ENTERED AT 12:11:15 ON 21 APR 2005
L4 4 S L3

Page 9

FILE 'CAOLD' ENTERED AT 12:11:26 ON 21 APR 2005
L5 0 S L3

FILE 'REGISTRY' ENTERED AT 12:11:32 ON 21 APR 2005

=> d 13 que stat
L1 STR



NH2 @62

VAR G1=NH2/60/48/49/52/61

VAR G2=NH2/52

VAR G3=ET/I-PR/N-PR

VPA 62-14/13/18 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

L3 34 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 302 ITERATIONS

SEARCH TIME: 00.00.01

34 ANSWERS

=> del_his.y

=> fil reg